Sentences with phrase «for human epidermal growth factor»

Triple negative breast cancer is a type of breast cancer that does not express receptors for the hormones estrogen and progesterone, or for human epidermal growth factor.

For years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cells — specifically those testing positive for human epidermal growth factor receptor 2 (HER2).

Not exact matches

Findings of the research, published April 22 in the journal Mucosal Immunology, reveal that a substance found in animal and human breast milk called epidermal growth factor, or EGF, blocks the activation of a protein responsible for unlocking the damaging immune cascade that culminates in NEC, a disease marked by the swift and irreversible death of intestinal tissue that remains one of the most - challenging - to - treat conditions.

Triple - negative cancers are so called because they do not express receptors for the hormones estrogen and progesterone, nor for HER2 (human epidermal growth factor 2), and hence patients with these cancers are not candidates for treatment with modern hormonal therapies or the highly effective HER2 - targeted drug Herceptin (trastuzumab).

PALLAS: Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR +) / Human Epidermal Growth Factor Receptor 2 (HER2)- Negative Early Breast Cancer

GEP testing is recommended for patients with early - stage, node - negative, estrogen receptor (ER)-- positive, human epidermal growth factor 2 (HER2)-- negative cancers.

Chemotherapy is a key part of the standard treatment regimen for triple - negative breast cancer patients whose cancer lacks expression of estrogen and progesterone receptors and the human epidermal growth factor receptor 2...

The human epidermal growth factor receptor - 2 (HER2) gene makes proteins responsible for maintaining healthy cell growth, division and repair of breast tissue.

These results, also presented at the 2015 European Cancer Congress (ECC2015, abstract # 5BA) today, which involve the group of 1,626 patients with a Recurrence Score between 0 and 10, demonstrated that 99.3 percent of node - negative, estrogen receptor (ER)- positive, human epidermal growth factor receptor 2 (HER2)- negative patients who met accepted guidelines for recommending chemotherapy in addition to hormonal therapy, had no distant recurrence at five years after treatment with hormonal therapy alone.

Many women are «triple negative» No one yet knows precisely why, but African - American women are roughly twice as likely as white women to have triple - negative breast cancer — so called because tumor cells in this particularly aggressive form of the disease test negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER - 2).

In highly proliferative lesions with increased Ki67, estrogen receptor was negative, but human epidermal growth factor receptor 2 was usually positive with a distribution that was similar to that reported for human intraepithelial lesions (7).